HR
FLNA

Howe & Rusling’s Filana Therapeutics FLNA Stock Holding History

Howe & Rusling’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-10
Closed – – 884
2022
Q3 		$0 Hold
10
– – ﹤0.01% 1178
2022
Q2 		$0 Hold
10
– – ﹤0.01% 1146
2022
Q1 		$0 Hold
10
– – ﹤0.01% 1070
2021
Q4 		$0 Hold
10
– – ﹤0.01% 1056
2021
Q3 		$1K Buy
10
+4
+67% +$334 ﹤0.01% 937
2021
Q2 		$1K Hold
6
– – ﹤0.01% 900
2021
Q1 		$0 Buy
+6
New +$236 ﹤0.01% 1007

Other funds holding FLNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCM
Gallacher Capital Management Lone Tree, Colorado $178M AUM 29.29% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Howe & Rusling's FLNA Position: Q4 2022 in Review

Howe & Rusling sold out of Filana Therapeutics (FLNA) in Q4 2022, closing a stake of 10 shares.

Howe & Rusling first reported a position in FLNA in Q1 2021 and held it in 7 quarters. The position peaked at $1K in Q3 2021. 153 funds tracked by Wall St. Rank hold FLNA as of Q4 2022.

  • Howe & Rusling reported no remaining Filana Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Howe & Rusling sold 10 Filana Therapeutics shares in Q4 2022.
  • Howe & Rusling first reported a position in Filana Therapeutics in Q1 2021 and held it in 7 quarters.
  • Howe & Rusling's Filana Therapeutics position peaked at $1K in Q3 2021.
  • 153 funds tracked by Wall St. Rank held Filana Therapeutics as of Q4 2022.

Based on Howe & Rusling's 13F filing for Q4 2022, filed 15 Feb 2023.